

**Minutes of the March 20, 2015  
Pharmacy & Therapeutics (P&T) Committee Meeting  
South Dakota Department of Social Services, Division of Medical Services**

**Members present**

Bill Ladwig, RPh; Dana Darger, RPh; M. Holland; M. Baack; T. Soundy; R. Holm; Lenny Petrik; Deb Farver; Kelley Oehlke

**DSS staff present**

Mike Jockheck, RPh

**Administrative business**

The P&T meeting was called to order by D. Darger at 1:00 p.m. The minutes of the December 12, 2014 meeting were presented. B. Ladwig made a motion to approve. D. Farver seconded the motion. The motion was approved unanimously.

**Prior authorization update and statistics**

The committee reviewed the prior authorization (PA) activity for January 2015. There were a total of 3,514 PAs processed in the month of January, with 99.91% of those requests responded to in less than eight hours. There were 2,799 requests (80%) received electronically and 715 requests (20%) received by fax.

**Analysis of the top 15 therapeutic classes**

The committee reviewed the top 15 therapeutic classes by total cost of claims from 10/1/2014 – 12/31/2014. The top five classes were antipsychotics, respiratory and CNS stimulants, central nervous system agents, misc., amphetamines, and insulins. The top 15 therapeutic classes make up 37.33% of total claims. The committee also reviewed the top 25 drugs based on total claims cost and number of claims. The top 25 drugs by claims cost make up 9.86% of total claims.

**Stimulant use in adults**

The committee reviewed stimulant use in adults at the December meeting. It was requested that a form be developed for the March meeting. After reviewing the form provided, the committee recommended changing the wording of the first line to “new prescription for a stimulant used for ADHD.” The committee also added “treated” to the criteria question asking if the patient was diagnosed before age 16. A motion was made by B. Ladwig to make recommended changes to the ADHD for adults form. M. Baack seconded the motion. The motion was approved unanimously.

**Otezla review**

The committee reviewed the prior authorization form provided for Otezla. P. McDermott, representing Celgene, spoke regarding Otezla. B. Ladwig made a motion to approve the Otezla PA form. K. Oehlke seconded the motion. The motion was approved unanimously.

### **GLP-1 receptor agonists review**

The committee reviewed the prior authorization form provided for GLP-1 receptor agonists. There was no public comment. The committee suggested removing “trial of metformin or a sulfonylurea.” R. Holm made a motion to approve the form. B. Ladwig seconded the motion. The motion was approved unanimously.

### **Topical therapies for onychomycosis review**

The committee reviewed the prior authorization form provided for topical therapies for onychomycosis. There was no public comment. R. Holm made a motion to approve the form. B. Ladwig seconded the motion. The motion was approved unanimously.

### **Prior authorization forms and criteria annual review**

The committee reviewed current prior authorization forms and criteria. Changes made include:

1. Brand-name narcotic form: add diagnosis to the form.
2. ARB form: must fail one ACE-I and a generic ARB.
3. Triptans: add rizatriptan and zolmitriptan to triptans that do not require PA
4. PPIs: add rabeprazole to PPIs that do not require PA
5. Nasal Steroids: remove Rhinocort
6. Oral Anticoagulants: add Savaysa to form

A motion was made by M. Holland to accept these changes. T. Soundy seconded the motion. The motion was approved unanimously.

### **Xtoro review**

The committee reviewed Xtoro clinical information. There was no public comment. The committee requested that a form be developed and brought back to the June meeting.

### **Hemangeol review**

The committee reviewed Hemangeol clinical information. There was no public comment. The committee requested that a form be developed and brought back to the June meeting.

### **Idiopathic pulmonary fibrosis review**

The committee reviewed agents used to treat idiopathic pulmonary fibrosis. Mike Donze, representing Boehringer Ingelheim, spoke regarding Ofev. The committee requested that a form be developed and brought back to the June meeting.

The next meeting is scheduled for June 5, 2015. B. Ladwig made a motion to adjourn the P&T Committee meeting. R. Holm seconded the motion. The motion passed unanimously and the meeting was adjourned.